Garen Bohlin - May 28, 2025 Form 4 Insider Report for Karyopharm Therapeutics Inc. (KPTI)

Role
Director
Signature
/s/ Nancy Smith, Attorney-in-Fact for Garen Bohlin
Stock symbol
KPTI
Transactions as of
May 28, 2025
Transactions value $
$0
Form type
4
Date filed
5/29/2025, 04:05 PM
Previous filing
May 19, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
BOHLIN GAREN G Director C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, NEWTON /s/ Nancy Smith, Attorney-in-Fact for Garen Bohlin 2025-05-29 0001254705

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KPTI Nonstatutory Stock Option (right to buy) Award $0 +4.6K $0.00 4.6K May 28, 2025 Common Stock 4.6K $4.48 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.
F2 This option vests as to 100% of the underlying shares on May 28, 2026.